businesswire.com
SITE Centers Announces Sale of Partnership Interests
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Partnership Interests.
SITE Centers Corp.SITCNYSE
LOADING
|||
Latest News
Loading news...
seekingalpha.com
U.S. Equity REITs Trade At Median 15% Discount To Analyst Price Targets
All 123 publicly traded US equity real estate investment trusts analyzed by S&P Global Market Intelligence traded below their respective consensus price target estimates. The specialty sector, which includes advertising, casinos, communications, data centers, energy infrastructure, farmland and timber, had the largest median implied upside to its consensus price target estimate, at 22.6%. REITs in the self-storage segment showed a 20.6% median implied upside to their consensus price target estimates, while the office sector followed closely at 18.7% and the residential sector at 15.4%.
businesswire.com
SITE Centers Announces Sale of Perimeter Pointe
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Perimeter Pointe.
seekingalpha.com
REIT Replay: U.S. REIT Indexes Fall During Week Ended Dec. 19
Indexes for US real estate investment trusts fell during the week ended Dec. 19. The Dow Jones Equity All REIT index dropped 1.18% over the recent week, while the MSCI US REIT index also fell 0.84%. The broader stock market indexes diverged for the week, with the S&P 500 up a slight 0.10% but the Dow Jones Industrial Average down 0.67%.
defenseworld.net
Caxton Associates LLP Sells 219,046 Shares of Site Centers Corp. $SITC
Caxton Associates LLP cut its stake in shares of Site Centers Corp. (NYSE: SITC) by 55.8% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 173,254 shares of the company's stock after selling 219,046 shares during the quarter. Caxton Associates LLP owned
businesswire.com
SITE Centers Announces Sale of Downtown Short Pump
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Downtown Short Pump.
defenseworld.net
Fisher Asset Management LLC Sells 182,310 Shares of Site Centers Corp. $SITC
Fisher Asset Management LLC lessened its holdings in shares of Site Centers Corp. (NYSE: SITC) by 62.2% in the second quarter, according to its most recent filing with the SEC. The firm owned 110,813 shares of the company's stock after selling 182,310 shares during the period. Fisher Asset Management LLC owned 0.21% of
businesswire.com
SITE Centers Provides Update on Disposition Activity and Go Forward Plan
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Provides Update on Disposition Activity and Go Forward Plan.
businesswire.com
SITE Centers Announces Special Common Stock Distribution and Debt Payoff
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Special Common Stock Distribution and Debt Payoff.
defenseworld.net
Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 14,531 Shares of Site Centers Corp. $SITC
Commonwealth of Pennsylvania Public School Empls Retrmt SYS reduced its position in Site Centers Corp. (NYSE: SITC) by 54.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,118 shares of the company's stock after selling 14,531 shares during the quarter. Commonwealth
businesswire.com
SITE Centers Announces Sales of Four Properties
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sales of Four Properties.
businesswire.com
SITE Centers Announces Sale of Paradise Village Gateway
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Paradise Village Gateway.
seekingalpha.com
REIT Replay: REIT Indexes Outperform Broader Markets During 1st Week Of November
Indexes tracking real estate investment trust stocks outperformed the broader stock market indexes during the first week of November. The Dow Jones Equity All REIT closed the recent week up 1.40%, while the MSCI US REIT (RMZ) index rose 1.50%. All of the Dow Jones US real estate property sector indexes logged increases this past week.
prnewswire.com
Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025
HONG KONG , Nov. 7, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) published the preclinical research data for its novel antagonistic monoclonal antibody targeting IL-1RAP, AK135, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held in National Harbor, Maryland. The results demonstrated that AK135 effectively targets IL-1RAP and blocks three key pro-inflammatory signaling pathways—IL-1, IL-33, and IL-36 at their source, thereby halting the transmission of inflammatory signals.
globenewswire.com
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB)
globenewswire.com
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio's ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, demonstrated promising monotherapy anti-tumor activity in patients with advanced solid tumors and generally well-tolerated safety profile Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, show potential for ctDNA as an early predictor for response to treatment with vilastobart in combination with atezolizumab in patients with MSS mCRC WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced new data across its portfolio, including preclinical data highlighting the best-in-class potential for Xilio's masked T cell engager platform and programs, as well as Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, and Phase 2 data related to circulating tumor DNA (ctDNA) for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4.
globenewswire.com
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients –
globenewswire.com
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive myeloid cells, including tumor-associated macrophages (TAMs) Pre-clinical data for IO Biotech's additional T-win vaccine candidate, IO170 targeting Transforming Growth Factor (TGF)-β, demonstrates induction of immune responses that could inhibit tumor growth and reduce lung metastasis Data presented at the Society for Immunotherapy of Cancer's Annual Meeting NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced new pre-clinical data for IO Biotech's next vaccine candidate, IO112, and additional candidate, IO170, will be presented at the Society for Immunotherapy of Cancer's 40th Annual Meeting (SITC 2025) in Maryland on November 5-9, 2025. “This new data is extremely important for our development path as it points toward more potential indications for our novel, immune-modulatory therapeutic vaccines to treat patients with a range of cancers,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech.
globenewswire.com
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to reconstitute immunity to treat cancer and immune disorders, today announced updated clinical results evaluating agenT-797, alone and in combination with anti-PD-1 therapy, in patients with advanced solid tumors refractory to all approved treatments presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 (Late Breaking Abstract #1344).
globenewswire.com
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today shared preclinical data at the 2025 Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland.